display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - adjuvant
breast cancer - adjuvant
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-522

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons